"id","rationale","uuid:ID","studyTitle","studyAcronym","versionIdentifier"
"StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","5ecdd672-104b-47d1-946b-0e157ec5bc8b","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","LZZT","2"
